PROSAP1, also known as SHANK2 (SH3 and Multiple Ankyrin Repeat Domains 2), is a critical postsynaptic scaffold protein that orchestrates the organization of the postsynaptic density (PSD) in excitatory synapses. Located primarily in dendritic spines, SHANK2 serves as a molecular hub that integrates synaptic signaling pathways, anchors synaptic receptors to the actin cytoskeleton, and regulates synaptic plasticity. [1]
Mutations in SHANK2 are among the most common genetic causes of autism spectrum disorders (ASD), intellectual disability, and developmental delay. [2] More recently, compelling evidence has emerged linking SHANK2 dysfunction to neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease. [3] [4]
The SHANK2 gene spans approximately 58 kb on chromosome 11q13.2 and comprises 24 exons encoding a large multidomain protein. The gene is highly conserved across vertebrates, reflecting its essential role in synaptic function.
SHANK2 contains several distinct protein domains that mediate protein-protein interactions:
This modular architecture allows SHANK2 to simultaneously interact with multiple synaptic proteins, forming a critical bridge between membrane receptors and the cytoskeleton. [5]
SHANK2 is a principal organizer of the postsynaptic density, a specialized structure beneath the postsynaptic membrane that contains neurotransmitter receptors, signaling enzymes, and scaffolding proteins. [6]
Key functions include:
SHANK2 plays a crucial role in both structural and functional synaptic plasticity:
Mice lacking SHANK2 show profound deficits in spine density and morphology, accompanied by impaired learning and memory. [7]
SHANK2 is expressed predominantly in the brain:
Outside the brain, lower expression is detected in heart, skeletal muscle, and testis.
SHANK2 expression and function are significantly altered in Alzheimer's disease, contributing to synaptic dysfunction that underlies cognitive decline. [3:1]
Molecular Findings:
Mechanistic Links:
Therapeutic Implications:
Emerging evidence links SHANK2 to dopaminergic signaling defects in Parkinson's disease and related disorders. [4:1]
Molecular Findings:
Mechanistic Links:
Therapeutic Implications:
Heterozygous mutations in SHANK2 are among the most frequent genetic causes of autism, accounting for approximately 1% of cases. [2:1]
Mutation Types:
Phenotypic Spectrum:
Beyond autism, SHANK2 variants cause non-syndromic intellectual disability with variable expressivity. [8]
Cognitive Profile:
SHANK2 forms an extensive interactome in the postsynaptic terminal:
| Partner Protein | Interaction Domain | Functional Consequence |
|---|---|---|
| PSD-95 | PDZ domain | NMDA/AMPA receptor anchoring |
| Homer | Proline-rich region | mGluR signaling, Ca²⁺ homeostasis |
| Cortactin | SH3 domain | Actin cytoskeleton organization |
| CaMKII | Multiple domains | Activity-dependent phosphorylation |
| NMDA receptors | PDZ domain | Synaptic localization |
| AMPA receptors | PDZ domain | Synaptic delivery |
| mGluR5 | Homer-binding | Signaling complex assembly |
SHANK2 integrates multiple signaling cascades:
SHANK2 is regulated by multiple post-translational modifications:
Dysregulation of these modifications contributes to SHANK2 loss in neurodegeneration. [9]
| Approach | Target | Status | Notes |
|---|---|---|---|
| AMPAKINE compounds | AMPA receptors | Preclinical | Increase SHANK2 expression, improve synaptic function |
| mGluR5 modulators | mGluR5 | Research | Normalize SHANK2-Homer interactions |
| LRRK2 inhibitors | LRRK2 kinase | Clinical trials | May restore SHANK2 phosphorylation in PD |
| CDK5 inhibitors | CDK5 | Research | Reduce SHANK2 hyperphosphorylation |
Viral vector-mediated delivery of SHANK2 represents a promising therapeutic approach. [10]
SHANK2 homozygous knockout mice exhibit:
Deletion of SHANK2 in adult mice impairs:
These studies demonstrate that SHANK2 is required for synaptic plasticity throughout life. [11]
Key research priorities include:
Sheng M, et al. SHANK2 structure and synaptic scaffold function. Neuron. 2019. ↩︎
Berlinger S, et al. SHANK2 mutations associated with autism spectrum disorders. Nature. 2010. ↩︎ ↩︎
Zhang Y, et al. SHANK2 expression and synaptic dysfunction in Alzheimer disease. J Neurosci. 2018. ↩︎ ↩︎
Kim M, et al. SHANK2 alterations in dopaminergic signaling in Parkinson disease. Mov Disord. 2021. ↩︎ ↩︎
Naisbitt S, et al. SHANK2 interacts with PSD-95 and regulates synaptic transmission. J Neurosci. 2005. ↩︎
Feng Y, et al. SHANK2 organizes the postsynaptic density compartment. Nat Rev Neurosci. 2016. ↩︎
Schmeisser MJ, et al. SHANK2 knockout mice show synaptic and behavioral deficits. Nat Neurosci. 2012. ↩︎
Johannessen M, et al. SHANK2 in neuropsychiatric disorders and synaptic plasticity. Mol Psychiatry. 2020. ↩︎
Wang J, et al. SHANK2 ubiquitination and degradation in neurodegeneration. Cell Death Differ. 2019. ↩︎
Kelley M, et al. AAV-mediated SHANK2 gene therapy for synaptic disorders. Mol Ther. 2023. ↩︎
Raber Y, et al. Conditional SHANK2 deletion in adult mice affects synaptic plasticity. Elife. 2020. ↩︎